MX2020001344A - Animales no humanos geneticamente modificados que expresan eritropoyetina de humano. - Google Patents
Animales no humanos geneticamente modificados que expresan eritropoyetina de humano.Info
- Publication number
- MX2020001344A MX2020001344A MX2020001344A MX2020001344A MX2020001344A MX 2020001344 A MX2020001344 A MX 2020001344A MX 2020001344 A MX2020001344 A MX 2020001344A MX 2020001344 A MX2020001344 A MX 2020001344A MX 2020001344 A MX2020001344 A MX 2020001344A
- Authority
- MX
- Mexico
- Prior art keywords
- human
- erythrocytes
- screens
- vivo
- animals expressing
- Prior art date
Links
- 210000003743 erythrocyte Anatomy 0.000 abstract 9
- 238000001727 in vivo Methods 0.000 abstract 4
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 102000044890 human EPO Human genes 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 241001465754 Metazoa Species 0.000 abstract 2
- 230000010437 erythropoiesis Effects 0.000 abstract 2
- 231100000331 toxic Toxicity 0.000 abstract 2
- 230000002588 toxic effect Effects 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 244000052637 human pathogen Species 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000004043 responsiveness Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 231100000167 toxic agent Toxicity 0.000 abstract 1
- 239000003440 toxic substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/524—Thrombopoietin, i.e. C-MPL ligand
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5403—IL-3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5437—IL-13
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/18—Testing for antimicrobial activity of a material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
- C12Y301/03048—Protein-tyrosine-phosphatase (3.1.3.48)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/12—Animals modified by administration of exogenous cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0337—Animal models for infectious diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0381—Animal model for diseases of the hematopoietic system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Environmental Sciences (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Veterinary Medicine (AREA)
- Urology & Nephrology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
Abstract
La presente invención se refiere a animales no humanos genéticamente modificados que expresan EPO de humano a partir del genoma del animal. También se proveen métodos para elaborar animales no humanos que expresan EPO de humano a partir del genoma del animal no humano, y métodos para utilizar los animales no humanos que expresan EPO de humano a partir del genoma del animal no humano. Estos animales y los métodos encuentran muchos usos en la técnica, incluyendo, por ejemplo, en el modelado de eritropoyesis humana y función de eritrocito; en el modelado de infección de eritrocitos por patógeno humano; en tamizajes in vivo para agentes que modulan la eritropoyesis y/o la función de eritrocito, por ejemplo, en un estado sano o en un estado patológico; en tamizajes para agentes que son tóxicos para los eritrocitos o los progenitores de eritrocito; en tamizajes in vivo para agentes que previenen contra, mitigan, o revierten los efectos tóxicos de agentes tóxicos en los eritrocitos o progenitores de eritrocito; en tamizajes in vivo de eritrocitos o progenitores de eritrocito provenientes de un individuo para predecir la capacidad de respuesta de un individuo a una terapia para enfermedad.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462000460P | 2014-05-19 | 2014-05-19 | |
PCT/US2015/031429 WO2015179317A2 (en) | 2014-05-19 | 2015-05-18 | Genetically modified non-human animals expressing human epo |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020001344A true MX2020001344A (es) | 2021-01-22 |
Family
ID=54011878
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016014995A MX2016014995A (es) | 2014-05-19 | 2015-05-18 | Animales no humanos geneticamente modificados que expresan eritropoyetina de humano. |
MX2020001344A MX2020001344A (es) | 2014-05-19 | 2015-05-18 | Animales no humanos geneticamente modificados que expresan eritropoyetina de humano. |
MX2021000858A MX2021000858A (es) | 2014-05-19 | 2016-11-15 | Animales no humanos geneticamente modificados que expresan eritropoyetina de humano. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016014995A MX2016014995A (es) | 2014-05-19 | 2015-05-18 | Animales no humanos geneticamente modificados que expresan eritropoyetina de humano. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021000858A MX2021000858A (es) | 2014-05-19 | 2016-11-15 | Animales no humanos geneticamente modificados que expresan eritropoyetina de humano. |
Country Status (17)
Country | Link |
---|---|
US (3) | US10463028B2 (es) |
EP (4) | EP3841877B1 (es) |
JP (4) | JP6672171B2 (es) |
KR (4) | KR102627332B1 (es) |
CN (2) | CN106536546B (es) |
AU (2) | AU2015264427B2 (es) |
CA (1) | CA2947309A1 (es) |
DK (3) | DK3482629T3 (es) |
ES (3) | ES2718732T3 (es) |
FI (1) | FI3841877T3 (es) |
IL (6) | IL288264B2 (es) |
MX (3) | MX2016014995A (es) |
MY (1) | MY179927A (es) |
PT (3) | PT3145307T (es) |
RU (1) | RU2711744C1 (es) |
SG (2) | SG10202002187WA (es) |
WO (1) | WO2015179317A2 (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8541646B2 (en) | 2009-10-06 | 2013-09-24 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice and engraftment |
RU2577978C2 (ru) | 2011-02-15 | 2016-03-20 | Ридженерон Фармасьютикалз, Инк. | Гуманизированные m-csf мыши |
KR102594390B1 (ko) | 2012-09-07 | 2023-10-27 | 예일 유니버시티 | 유전적으로 변형된 비-인간 동물 및 이것들의 사용 방법 |
EP4389764A2 (en) | 2012-11-05 | 2024-06-26 | Regeneron Pharmaceuticals, Inc. | Genetically modified non-human animals and methods of use thereof |
KR102627332B1 (ko) * | 2014-05-19 | 2024-01-26 | 리제너론 파마슈티칼스 인코포레이티드 | 인간 epo를 발현하는 유전자 변형된 비-인간 동물 |
PT3157956T (pt) | 2014-06-19 | 2020-04-09 | Regeneron Pharma | Animais não humanos com um gene 1 de morte programada humanizada em células |
RS63410B1 (sr) | 2014-11-24 | 2022-08-31 | Regeneron Pharma | Ne-humane životinje koje eksprimiraju humanizovani cd3 kompleks |
KR102313073B1 (ko) | 2014-12-05 | 2021-10-18 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화 분화 클러스터 47 유전자를 가진 비인간 동물 |
PT3282835T (pt) * | 2015-04-13 | 2023-07-25 | Univ Yale | Ratinhos knockin de sirpa-il15 humanizadas e métodos de utilização dos mesmos |
US10306874B2 (en) | 2015-11-20 | 2019-06-04 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized lymphocyte-activation gene 3 |
ES2908669T3 (es) * | 2016-02-04 | 2022-05-03 | Regeneron Pharma | Animales no humanos que tienen un gen ANGPTL8 modificado genéticamente |
KR102493894B1 (ko) | 2016-02-29 | 2023-01-31 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화 tmprss 유전자를 갖는 설치류 |
SG11201901107RA (en) * | 2016-08-11 | 2019-03-28 | Jackson Lab | Methods and compositions relating to improved human red blood cell survival in genetically modified immunodeficient non-human animals |
US20190320633A1 (en) * | 2016-11-30 | 2019-10-24 | The Jackson Laboratory | Humanized mouse model with improved human innate immune cell development |
MX2020003589A (es) | 2017-09-29 | 2020-07-22 | Regeneron Pharma | Animales no humanos que comprenden un locus ttr humanizado y metodos de uso. |
JP7104930B2 (ja) * | 2017-10-18 | 2022-07-22 | マイキャン・テクノロジーズ株式会社 | 不死化赤血球前駆細胞由来の血球様細胞を用いたマラリア原虫等の維持培養・感染評価に適した細胞の決定方法 |
SG11202002456WA (en) | 2017-11-30 | 2020-04-29 | Regeneron Pharma | Non-human animals comprising a humanized trkb locus |
JP7328243B2 (ja) | 2018-03-26 | 2023-08-16 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 治療薬を試験するためのヒト化げっ歯類 |
CA3098040A1 (en) | 2018-07-16 | 2020-01-23 | Regeneron Pharmaceuticals, Inc. | Non-human animal models of ditra disease and uses thereof |
CN111172190B (zh) * | 2018-12-25 | 2021-07-30 | 百奥赛图江苏基因生物技术有限公司 | 人源化细胞因子csf2基因改造非人动物的构建方法及应用 |
CN111073907A (zh) * | 2018-12-25 | 2020-04-28 | 百奥赛图江苏基因生物技术有限公司 | 人源化细胞因子csf1基因改造非人动物的构建方法及应用 |
CA3133360A1 (en) | 2019-04-04 | 2020-10-08 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized coagulation factor 12 locus |
US11891618B2 (en) | 2019-06-04 | 2024-02-06 | Regeneron Pharmaceuticals, Inc. | Mouse comprising a humanized TTR locus with a beta-slip mutation and methods of use |
AU2020289581A1 (en) | 2019-06-07 | 2021-11-18 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized albumin locus |
CN112700604A (zh) * | 2021-01-11 | 2021-04-23 | 深圳市罗湖区人民医院 | 一种自助核酸检测方法及装置 |
US20230190703A1 (en) * | 2021-12-20 | 2023-06-22 | Allen Qian | Treating sar-cov-2 related health problems |
US20240102045A1 (en) | 2022-07-19 | 2024-03-28 | Regeneron Pharmaceuticals, Inc. | Vectors, genetically modified cells, and genetically modified non-human animals comprising the same |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4870009A (en) | 1982-11-22 | 1989-09-26 | The Salk Institute For Biological Studies | Method of obtaining gene product through the generation of transgenic animals |
US4736866A (en) | 1984-06-22 | 1988-04-12 | President And Fellows Of Harvard College | Transgenic non-human mammals |
US5573930A (en) | 1985-02-05 | 1996-11-12 | Cetus Oncology Corporation | DNA encoding various forms of colony stimulating factor-1 |
WO1988003173A2 (en) | 1986-10-24 | 1988-05-05 | Cetus Corporation | New forms of colony stimulating factor-1 |
EP0322240B1 (en) | 1987-12-23 | 1995-03-01 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric immunocompromised mammals and their use |
JP2981486B2 (ja) | 1988-06-14 | 1999-11-22 | メディカル・バイオロジー・インスティチュート | 哺乳動物の免疫系研究方法 |
DE69131331T2 (de) | 1990-01-15 | 2000-03-02 | Yeda Res & Dev | Dauerhafte Verpflanzung und Entwicklung menschlicher hämatopoietischer Zellinien bei normalen Säugetieren |
US5652373A (en) | 1990-01-15 | 1997-07-29 | Yeda Research And Development Co. Ltd. | Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems |
US5849288A (en) | 1990-01-15 | 1998-12-15 | Yeda Research And Development Co. Ltd. | Method for production of monoclonal antibodies in chimeric mice or rats having xenogeneic antibody-producing cells |
ES2090332T3 (es) | 1990-05-03 | 1996-10-16 | Systemix Inc | Tejido linfoide humano en un hospedador inmunocomprometido. |
US5633426A (en) | 1990-05-25 | 1997-05-27 | Systemix, Inc. | In vivo use of human bone marrow for investigation and production |
CA2064075A1 (en) | 1990-05-25 | 1991-11-26 | Charles M. Baum | Human peripheral blood cells in an immunocompromised host |
WO1992013501A1 (en) | 1991-02-11 | 1992-08-20 | Ommaya Ayub K | Spinal fluid driven artificial organ |
US5222982A (en) | 1991-02-11 | 1993-06-29 | Ommaya Ayub K | Spinal fluid driven artificial organ |
EP0517199A1 (en) | 1991-06-04 | 1992-12-09 | Yeda Research And Development Company, Ltd. | Durable engraftment of human tissue and cells in normal mammals |
WO1993005796A1 (en) | 1991-09-19 | 1993-04-01 | The Scripps Research Institute | Method for producing human antibodies in a non-human animal, and animals therefor |
DE69229254T2 (de) | 1991-10-30 | 1999-09-23 | Idemitsu Kosan Co | Verfahren zur Herstellung von menschlichen Lymphozyten und menschlichen Antikörpern; und so hergestellte Antikörper |
US6353150B1 (en) | 1991-11-22 | 2002-03-05 | Hsc Research And Development Limited Partnership | Chimeric mammals with human hematopoietic cells |
WO1993018144A1 (en) | 1992-03-05 | 1993-09-16 | The Trustees Of Columbia University Of The City Of New York | Recombination activating gene deficient animal |
US5866757A (en) | 1992-06-02 | 1999-02-02 | Yeda Research And Development Co. Ltd. | Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems |
US6018096A (en) | 1993-05-03 | 2000-01-25 | Surrogen, Inc. | Animal model for engraftment, proliferation and differentiation of human hematopoietic stem cells |
CA2103693A1 (en) | 1993-08-06 | 1995-02-07 | Steven Gallinger | Animal model of the human immune system |
WO1996003495A1 (en) | 1994-07-27 | 1996-02-08 | Merck & Co., Inc. | Bradykinin b2 receptor modified transgenic non-human animals |
US6455756B1 (en) | 1994-08-12 | 2002-09-24 | Novartis Ag | Long term xenogeneic myeloid and lymphoid cell production in chimeric immunocompromised mice |
US7273753B2 (en) | 1996-08-02 | 2007-09-25 | Center Of Blood Research | Purification and uses of dendritic cells and monocytes |
US6248721B1 (en) | 1997-04-09 | 2001-06-19 | Lung-Ji Chang | Method of using mouse model for evaluation of HIV vaccines |
CA2284689C (en) | 1997-04-09 | 2009-10-06 | Lung-Ji Chang | Animal model for evaluation of vaccines |
US20030028911A1 (en) | 1999-08-31 | 2003-02-06 | Manley Huang | Transgenic mammal capable of facilitating production of donor-specific functional immunity |
JP2003508038A (ja) | 1999-08-31 | 2003-03-04 | ジェネンコア インターナショナル インコーポレーテッド | ドナー特異的機能性免疫の産生を容易にすることができるトランスジェニック哺乳類 |
JP2004500810A (ja) | 1999-12-09 | 2004-01-15 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | Il−6様ポリヌクレオチド、ポリペプチド、および抗体 |
US6864061B2 (en) | 2000-09-14 | 2005-03-08 | Genetrol Biotherapeutics, Inc. | Method for screening compounds for anti-inflammatory activity |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
AU2002363322A1 (en) | 2001-10-26 | 2003-05-19 | Large Scale Biology Corporation | Endothelial cell derived hemotopoietic growth factor |
EP1452093A4 (en) | 2001-11-15 | 2007-08-15 | Kirin Brewery | CHIMERIC ANIMALS |
AU2003281309A1 (en) | 2002-07-05 | 2004-01-23 | Kirin Beer Kabushiki Kaisha | Novel undifferentiated stem cells contained in cord blood, bone marrow, peripheral blood or the like |
CN101250553A (zh) | 2002-07-13 | 2008-08-27 | 上海医学遗传研究所 | 一种促人血小板生成素表达载体及其构建方法 |
CA2496233A1 (en) | 2002-09-09 | 2004-03-18 | California Institute Of Technology | Methods and compositions for the generation of humanized mice |
EP1418185A1 (en) | 2002-11-11 | 2004-05-12 | Aventis Pharma Deutschland GmbH | Use of EDG2 receptor in an animal model of heart failure |
US7402728B2 (en) | 2002-12-16 | 2008-07-22 | Genentech, Inc. | Transgenic mice expressing human CD20 and/or CD16 |
PT1802193E (pt) | 2004-10-19 | 2014-06-23 | Regeneron Pharma | Método para gerar um murganho homozigótico para uma modificação genética |
US7759541B2 (en) | 2004-12-13 | 2010-07-20 | Iti Life Sciences | Transgenic animals for assessing drug metabolism and toxicity |
GB2434578A (en) | 2006-01-26 | 2007-08-01 | Univ Basel | Transgenic animals |
ES2618787T5 (es) | 2006-04-25 | 2022-10-21 | Univ California | Administración de factores de crecimiento para el tratamiento de trastornos del SNC |
EP1878342A1 (en) | 2006-07-13 | 2008-01-16 | Institut Pasteur | Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses |
US20080081064A1 (en) | 2006-09-28 | 2008-04-03 | Surmodics, Inc. | Implantable Medical Device with Apertures for Delivery of Bioactive Agents |
EP2088854A1 (en) | 2006-12-05 | 2009-08-19 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Improved xenogenic immune system in a non-human mammal |
EP2155873B1 (en) | 2007-05-23 | 2016-11-09 | Sangamo BioSciences, Inc. | Methods and compositions for increased transgene expression |
EP2176414A4 (en) * | 2007-08-08 | 2011-01-26 | Cho A Pharm Co Ltd | EXPRESSION VECTOR FOR BREAST-DRY SPECIFIC HUMAN ERYTHROPOIETIN, TRANSGENIC ANIMAL AND METHOD FOR THE PRODUCTION OF HUMAN ERYTHROPOIETIN USING THEREOF |
GB0718029D0 (en) | 2007-09-14 | 2007-10-24 | Iti Scotland Ltd | Two step cluster deletion and humanisation |
WO2009042917A1 (en) | 2007-09-28 | 2009-04-02 | The General Hospital Corporation | Methods and compositions for antibody production |
JP2011510750A (ja) | 2008-01-29 | 2011-04-07 | クライマン、ギルバート・エイチ | 薬物送達デバイス、キット及びそれらの方法 |
WO2009114400A1 (en) | 2008-03-07 | 2009-09-17 | Regeneron Pharmaceuticals, Inc. | Es cell-derived mice from diploid host embryo injection |
US20120251528A1 (en) | 2009-06-29 | 2012-10-04 | Leskov Ilya B | Non-Human Mammal Model Of Human Hematopoietic Cancer |
CN102725400A (zh) * | 2009-06-29 | 2012-10-10 | 麻省理工学院 | 制造人源化的非人类哺乳动物的方法 |
RU2425880C2 (ru) * | 2009-07-30 | 2011-08-10 | Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН | Способ получения трансгенных мышей |
US8541646B2 (en) | 2009-10-06 | 2013-09-24 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice and engraftment |
WO2012040207A2 (en) | 2010-09-20 | 2012-03-29 | Yale University | HUMAM SIRPAα TRANSGENIC ANIMALS AND THEIR METHODS OF USE |
WO2012051572A1 (en) | 2010-10-15 | 2012-04-19 | Massachusetts Institute Of Technology | A humanized non-human mammal model of malaria and uses thereof |
RU2577978C2 (ru) | 2011-02-15 | 2016-03-20 | Ридженерон Фармасьютикалз, Инк. | Гуманизированные m-csf мыши |
WO2012137449A1 (ja) * | 2011-04-05 | 2012-10-11 | 株式会社 東北テクノアーチ | Epo欠損GFP貧血マウス |
JP6120451B2 (ja) | 2011-10-28 | 2017-04-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | ヒト化il−6および/またはil−6受容体 |
KR102594390B1 (ko) | 2012-09-07 | 2023-10-27 | 예일 유니버시티 | 유전적으로 변형된 비-인간 동물 및 이것들의 사용 방법 |
EP4389764A2 (en) | 2012-11-05 | 2024-06-26 | Regeneron Pharmaceuticals, Inc. | Genetically modified non-human animals and methods of use thereof |
RS64573B1 (sr) | 2013-09-23 | 2023-10-31 | Regeneron Pharma | Ne-humana životinja sa humanizovanim signalno-regulatornim proteinskim genom |
EP3461331A1 (en) | 2013-10-15 | 2019-04-03 | Regeneron Pharmaceuticals, Inc. | Humanized il-15 animals |
WO2016010601A2 (en) | 2014-04-23 | 2016-01-21 | The Florida State University Research Foundation, Inc. | Adaptive nonlinear model predictive control using a neural network and input sampling |
KR102627332B1 (ko) * | 2014-05-19 | 2024-01-26 | 리제너론 파마슈티칼스 인코포레이티드 | 인간 epo를 발현하는 유전자 변형된 비-인간 동물 |
PT3282835T (pt) | 2015-04-13 | 2023-07-25 | Univ Yale | Ratinhos knockin de sirpa-il15 humanizadas e métodos de utilização dos mesmos |
-
2015
- 2015-05-18 KR KR1020237029511A patent/KR102627332B1/ko active IP Right Grant
- 2015-05-18 ES ES15756500T patent/ES2718732T3/es active Active
- 2015-05-18 PT PT15756500T patent/PT3145307T/pt unknown
- 2015-05-18 IL IL288264A patent/IL288264B2/en unknown
- 2015-05-18 ES ES20209073T patent/ES2964597T3/es active Active
- 2015-05-18 SG SG10202002187WA patent/SG10202002187WA/en unknown
- 2015-05-18 MX MX2016014995A patent/MX2016014995A/es active IP Right Grant
- 2015-05-18 RU RU2016149565A patent/RU2711744C1/ru active
- 2015-05-18 EP EP20209073.4A patent/EP3841877B1/en active Active
- 2015-05-18 PT PT182140772T patent/PT3482629T/pt unknown
- 2015-05-18 CN CN201580028410.XA patent/CN106536546B/zh active Active
- 2015-05-18 PT PT202090734T patent/PT3841877T/pt unknown
- 2015-05-18 DK DK18214077.2T patent/DK3482629T3/da active
- 2015-05-18 FI FIEP20209073.4T patent/FI3841877T3/fi active
- 2015-05-18 DK DK20209073.4T patent/DK3841877T3/da active
- 2015-05-18 SG SG11201608999SA patent/SG11201608999SA/en unknown
- 2015-05-18 WO PCT/US2015/031429 patent/WO2015179317A2/en active Application Filing
- 2015-05-18 AU AU2015264427A patent/AU2015264427B2/en active Active
- 2015-05-18 KR KR1020167031920A patent/KR102446689B1/ko active IP Right Grant
- 2015-05-18 EP EP23195231.8A patent/EP4306648A3/en active Pending
- 2015-05-18 DK DK15756500.3T patent/DK3145307T3/en active
- 2015-05-18 MX MX2020001344A patent/MX2020001344A/es unknown
- 2015-05-18 EP EP15756500.3A patent/EP3145307B1/en active Active
- 2015-05-18 CN CN202110382598.5A patent/CN113045639A/zh active Pending
- 2015-05-18 EP EP18214077.2A patent/EP3482629B1/en active Active
- 2015-05-18 MY MYPI2016703949A patent/MY179927A/en unknown
- 2015-05-18 KR KR1020247001740A patent/KR20240017405A/ko not_active Application Discontinuation
- 2015-05-18 KR KR1020227032545A patent/KR102574155B1/ko active IP Right Grant
- 2015-05-18 ES ES18214077T patent/ES2854276T3/es active Active
- 2015-05-18 US US14/715,446 patent/US10463028B2/en active Active
- 2015-05-18 CA CA2947309A patent/CA2947309A1/en active Pending
- 2015-05-18 JP JP2016565240A patent/JP6672171B2/ja active Active
-
2016
- 2016-10-31 IL IL248646A patent/IL248646B/en active IP Right Grant
- 2016-11-15 MX MX2021000858A patent/MX2021000858A/es unknown
-
2019
- 2019-11-01 US US16/672,042 patent/US11766032B2/en active Active
-
2020
- 2020-03-04 JP JP2020036588A patent/JP7130012B2/ja active Active
- 2020-04-05 IL IL273812A patent/IL273812B/en active IP Right Grant
-
2021
- 2021-01-17 IL IL280214A patent/IL280214B/en unknown
- 2021-12-14 AU AU2021286279A patent/AU2021286279A1/en active Pending
-
2022
- 2022-05-02 JP JP2022075728A patent/JP7385703B2/ja active Active
- 2022-09-08 IL IL296315A patent/IL296315B1/en unknown
-
2023
- 2023-08-10 US US18/448,062 patent/US20240074414A1/en active Pending
- 2023-11-10 JP JP2023192177A patent/JP2024009054A/ja active Pending
-
2024
- 2024-05-16 IL IL312888A patent/IL312888A/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021000858A (es) | Animales no humanos geneticamente modificados que expresan eritropoyetina de humano. | |
MX2022001201A (es) | Ratones con genes insertados de sirp¿-il15 humanizadas y métodos para usarlos. | |
CY1121410T1 (el) | Μη-ανθρωπινα ζωα που εχουν ενα εξανθρωποποιημενο γονιδιο ρυθμιστικης πρωτεϊνης σηματος | |
CY1121405T1 (el) | Εξανθρωποποιημενα il-15 ζωα | |
CY1121223T1 (el) | Ποντικοι οι οποιοι εκφραζουν ανθρωποποιημενο μειζον συμπλεγμα ιστοσυμβατοτητας | |
CY1123714T1 (el) | Μη-ανθρωπινα ζωα που εκφραζουν ανθρωποποιημενο cd3 συμπλοκο | |
CY1124089T1 (el) | Μη ανθρωπινα ζωα που εχουν ενα εξανθρωπισμενο γονιδιο συμπλεγματος διαφοροποιησης 47 | |
CY1119071T1 (el) | Εξανθρωποποιημενα il-7 τρωκτικα | |
MY162984A (en) | Humanized m-csf mice | |
MX2019005251A (es) | Animales no humanos geneticamente modificados y metodos de uso de los mismos. | |
EA201692510A1 (ru) | Композиции и способы для экспрессии рнк-проводников crispr с использованием промотора h1 | |
NZ746680A (en) | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same | |
MX2013010343A (es) | Composicion y metodos para el transplante de microbiota de colon. | |
MY175954A (en) | Light-sensitive ion-passing molecules | |
BR112016011003A2 (pt) | animal roedor geneticamente modificado, célula tronco embrionária de camundongo, embrião de camundongo, e, métodos para fabricar um animal roedor e para enxertar células humanas em um camundongo | |
MX2014012977A (es) | Anticuerpos anti-cd22. | |
MX2016014306A (es) | Marcadores para terapia con lipoproteinas de alta densidad (hdl). | |
IL277353A (en) | Non-human animals genetically modified to generate therapeutic antibodies against peptide-MHC complexes, methods of preparation and uses thereof | |
DK4000662T3 (da) | Kunstigt lungesystem og anvendelsesfremgangsmåder, der ikke udføres på den levende menneske- eller dyrekrop | |
EP3678484A4 (en) | MODIFIED ANIMAL ORGANS FOR USE IN SURGICAL SIMULATORS | |
MA41645A (fr) | Anticorps issus de génie génétique spécifiques au site et méthodes d'utilisation | |
MY185691A (en) | An asseointegrable device | |
IL282829A (en) | An animal model for amplifying human or animal circular cancer cells | |
MX2017007295A (es) | Modelo animal de ojo seco y metodos de uso de dichos animales. | |
CR20150317A (es) | Control de malezas sinergístico a partir de aplicaciones de aminociclopiraclor y ácido 2,4 diclorofenoxiacético (2,4-d) |